Last reviewed · How we verify

Amlodipine placebos — Competitive Intelligence Brief

Amlodipine placebos (Amlodipine placebos) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker (dihydropyridine). Area: Cardiovascular.

marketed Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Amlodipine placebos (Amlodipine placebos) — Shenzhen Ausa Pharmed Co.,Ltd. Amlodipine is a calcium channel blocker that relaxes blood vessels and reduces heart workload to lower blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Amlodipine placebos TARGET Amlodipine placebos Shenzhen Ausa Pharmed Co.,Ltd marketed Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel
nifedipine controlled release tablets nifedipine controlled release tablets Guangzhou First People's Hospital marketed Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel
Amlodipine + Perindopril Amlodipine + Perindopril Centre for Chronic Disease Control, India marketed Calcium channel blocker + ACE inhibitor combination L-type voltage-gated calcium channels; Angiotensin-converting enzyme (ACE)
Losartan/amlodipine or losartan/hydrochlorothiazide Losartan/amlodipine or losartan/hydrochlorothiazide Yokohama City University Medical Center marketed Angiotensin II receptor blocker combination (ARB + calcium channel blocker or ARB + thiazide diuretic) Angiotensin II type 1 receptor (AT1R); L-type voltage-gated calcium channels (amlodipine) or sodium-chloride cotransporter (hydrochlorothiazide)
Lercanidipine/enalapril fixed combination Lercanidipine/enalapril fixed combination Meir Medical Center marketed Calcium channel blocker / ACE inhibitor combination L-type voltage-gated calcium channels; Angiotensin-converting enzyme (ACE)
Olmesartan medoxomil ＋Azelnidipine Olmesartan medoxomil ＋Azelnidipine Jichi Medical University marketed Antihypertensive combination (ARB + calcium channel blocker) Angiotensin II type 1 receptor (AT1R) and L-type voltage-gated calcium channels
Eplerenone vs Amlodipine Eplerenone vs Amlodipine Brigham and Women's Hospital marketed Aldosterone antagonist (eplerenone); Dihydropyridine calcium channel blocker (amlodipine) Mineralocorticoid receptor (eplerenone); L-type voltage-gated calcium channel (amlodipine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker (dihydropyridine) class)

  1. Bayer · 2 drugs in this class
  2. Beijing Tiantan Hospital · 2 drugs in this class
  3. GlaxoSmithKline · 1 drug in this class
  4. Guangzhou First People's Hospital · 1 drug in this class
  5. Organon and Co · 1 drug in this class
  6. Peking University First Hospital · 1 drug in this class
  7. Pfizer Inc. · 1 drug in this class
  8. SK Chemicals Co., Ltd. · 1 drug in this class
  9. Shanghai Jiao Tong University School of Medicine · 1 drug in this class
  10. Shanghai Shyndec Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Amlodipine placebos — Competitive Intelligence Brief. https://druglandscape.com/ci/amlodipine-placebos. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: